Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:698:279-94.
doi: 10.1007/978-1-60761-999-4_21.

Use of human mesenchymal stem cells as alternative source of smooth muscle cells in vessel engineering

Zhaodi Gong  1 , Laura E Niklason
Affiliations

Use of human mesenchymal stem cells as alternative source of smooth muscle cells in vessel engineering

Zhaodi Gong et al. Methods Mol Biol. 2011.

Abstract

Adult stem cell-derived smooth muscle cells (SMC) may be a promising source of cells for applications in regenerative medicine, including cardiovascular tissue engineering. Primary SMC from native vessels may have limited proliferative capacity and reduced collagen production when sourced from elderly donors, who are the patients in need of vascular grafts due to coronary disease or peripheral arterial disease. Our recent work showed that the ability of human bone marrow-derived mesenchymal stem cells (hMSCs) to differentiate into SMC was modulated by various growth factors, matrix proteins, and mechanical forces. In addition, the components of the culture medium play a very important role in SMC differentiation from hMSCs. In this chapter, we will summarize our experience with the impact of various factors on SMC differentiation from hMSCs. Based upon our findings regarding growth factors, cyclic strain and matrix proteins, a two-phase vessel regeneration culture protocol including a 4-week proliferation phase and a 4-week differentiation phase was developed to optimize proliferation and SMC differentiation of hMSCs consecutively.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Measurement of the large and small tubing for the flow system.
Fig. 2
Fig. 2
General schematic of the bioreactor/mesh setup before (a) and after (b) the assembly on the launch day.
Fig. 3
Fig. 3
Flow system set-up.
Fig. 4
Fig. 4
Pictures of two glass bioreactors in an incubator (a) and two engineered vessels (b).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kaushal S, Amiel GE, Guleserian KJ, Sharpira OM, Perry T, Sutherland FW, Rabkin E, Moran AM, Schoen FJ, Atala A, Soker S, Bischoff J, Mayer JE. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat Med. 2001;7:1035–1040. - PMC - PubMed
    1. Kadner A, Heorstrup SP, Zund G, Eid K, Maurus C, Melinitchouk S, Grunenfelder J, Turina MI. A new source for cardiovascular tissue engineering: Human bone marrow stromal cells. Eur J Cardiothorac Surg. 2002;21:1055–1060. - PubMed
    1. Hoerstrup SP, Kadner A, Melnitchouk S, Trojan A, Eid K, Tracy J, Sodian R, Visjager JF, Kolb SA, Grunenfelder J, Zund G, Turina MI. Tissue engineering of functional trileaflet heart valves from human marrow stromal cells. Circulation. 2002;106:I143–I150. - PubMed
    1. Perry TE, Kaushal S, Sutherland FW, Guleserian KJ, Bischoff J, Sacks M, Mayer JE. Bone marrow as a cell source for tissue engineering heart valves. Ann Thorac Surg. 2003;75:761–767. - PubMed
    1. Matsumura G, Miyagawa-Tomita S, Shin’oka T, Ikada Y, Kurosawa H. First evidence that bone marrow cells contribute to the construction of tissue-engineered vascular autografts in vivo. Circulation. 2003;108:1729–1734. - PubMed

Publication types

LinkOut - more resources